Literature DB >> 19387567

Selenoprotein W modulates control of cell cycle entry.

Wayne Chris Hawkes1, Thomas T Y Wang, Zeynep Alkan, B Diane Richter, Kevin Dawson.   

Abstract

The present study was conducted to identify targets of selenium (Se) provided to cultured human cells in physiologically relevant doses and forms. Breast and prostate epithelial cells were supplemented with Se provided as 100 nM sodium selenite or high-Se serum and gene expression was profiled with DNA microarrays. Pure sodium selenite affected expression of 560 genes in MCF-10A breast cells, including 60 associated with the cell cycle (p = 2.8 x 10(-16)). Selenoprotein W (SEPW1) was the only selenoprotein messenger RNA (mRNA) increased by both sodium selenite (specific) and high-Se serum (physiologic). SEPW1 small interfering RNA inhibited G1-phase progression and increased G1-phase gene transcripts, while decreasing S-phase and G2/M-phase gene transcripts, indicating the cell cycle was interrupted at the G1/S transition. SEPW1 mRNA levels were maximal during G1-phase, dropped after the G1/S transition and increased again after G2/M-phase. SEPW1-underexpressing prostate cells had increased mRNA for BCL2, which can induce a G1 arrest, and decreased mRNA for RBBP8 and KPNA2, which modulate the Rb/p53 checkpoint pathway. These results suggest that SEPW1 and the G1/S transition are physiological targets of Se in breast and prostate epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19387567     DOI: 10.1007/s12011-009-8367-0

Source DB:  PubMed          Journal:  Biol Trace Elem Res        ISSN: 0163-4984            Impact factor:   3.738


  11 in total

1.  Delayed cell cycle progression in selenoprotein W-depleted cells is regulated by a mitogen-activated protein kinase kinase 4-p38/c-Jun NH2-terminal kinase-p53 pathway.

Authors:  Wayne Chris Hawkes; Zeynep Alkan
Journal:  J Biol Chem       Date:  2012-06-22       Impact factor: 5.157

Review 2.  The emerging role of selenium metabolic pathways in cancer: New therapeutic targets for cancer.

Authors:  Kalishwaralal Kalimuthu; Chenicheri K Keerthana; Manikandan Mohan; Jaison Arivalagan; Johnson Retnaraj Samuel Selvan Christyraj; Michael A Firer; Mohammad Haroon Asif Choudry; Ruby John Anto; Yong J Lee
Journal:  J Cell Biochem       Date:  2021-12-21       Impact factor: 4.429

3.  Regulation of redox signaling by selenoproteins.

Authors:  Wayne Chris Hawkes; Zeynep Alkan
Journal:  Biol Trace Elem Res       Date:  2010-03-20       Impact factor: 3.738

Review 4.  Selenium, Selenoproteins, and Heart Failure: Current Knowledge and Future Perspective.

Authors:  Ali A Al-Mubarak; Peter van der Meer; Nils Bomer
Journal:  Curr Heart Fail Rep       Date:  2021-04-09

5.  Metals and breast cancer: risk factors or healing agents?

Authors:  Ana-Maria Florea; Dietrich Büsselberg
Journal:  J Toxicol       Date:  2011-07-24

Review 6.  Biomarkers of selenium status.

Authors:  Gerald F Combs
Journal:  Nutrients       Date:  2015-03-31       Impact factor: 5.717

Review 7.  Asparaginase treatment side-effects may be due to genes with homopolymeric Asn codons (Review-Hypothesis).

Authors:  Julian Banerji
Journal:  Int J Mol Med       Date:  2015-07-15       Impact factor: 4.101

8.  BMP4 inhibits the proliferation of breast cancer cells and induces an MMP-dependent migratory phenotype in MDA-MB-231 cells in 3D environment.

Authors:  Minna Ampuja; Riikka Jokimäki; Kati Juuti-Uusitalo; Alejandra Rodriguez-Martinez; Emma-Leena Alarmo; Anne Kallioniemi
Journal:  BMC Cancer       Date:  2013-09-22       Impact factor: 4.430

9.  Accessing human selenoproteins through chemical protein synthesis.

Authors:  L Dery; P Sai Reddy; S Dery; R Mousa; O Ktorza; A Talhami; N Metanis
Journal:  Chem Sci       Date:  2016-11-01       Impact factor: 9.825

10.  Deletion of glutathione peroxidase-2 inhibits azoxymethane-induced colon cancer development.

Authors:  Mike F Müller; Simone Florian; Stefanie Pommer; Martin Osterhoff; R Steven Esworthy; Fong-Fong Chu; Regina Brigelius-Flohé; Anna P Kipp
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.